Imugene gains global rights to Precision BioSciences’ most advanced program, an allogeneic cell therapy for advanced cases of blood cancer. Precision will now focus on in vivo gene editing therapies, some of which is partnered with Novartis and Eli Lilly.
Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, such as sickle cell disease. One of the goals of the alliance is to make genetic medicines more globally accessible.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Biotech startup iECURE is based on work from the University of Pennsylvania scientist, who has been researching ways to use in vivo gene editing as a way to “knock in” healthy versions of a gene to treat rare liver diseases. The company, which will develop therapeutic candidates from Penn, has raised $50 million in Series A financing.
The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
Hospitals - especially in Europe - anticipate growing interest from international patients. But a wave of industry consolidation is debatable.
Making CAR-T therapeutics allogeneic would significantly improve its scalability - but it's been a tough goal to conceive. Precision BioSciences' genome editing deal with Baxalta could make it a reality.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The market potential of CRISPR technology has been legitimized by Editas Medicine's impressive, $120 million fundraise. Here are six more biotechs shaping the CRISPR landscape look like now? And what other players are in this game?
North Carolina biotechnology firm Precision BioSciences is on its way to strengthening patent protection for its genome engineering technology. The U.S. Patent and Trademark Office has issued a “notice of allowance” for a Precision patent application related to one of the Durham, North Carolina company’s genome engineering methods. The written notice means that the USPTO […]
North Carolina biotechnology company Precision BioSciences has secured a patent victory for its genome engineering technology. The U.S. Patent and Trademark Office has rejected claims from French company Cellectis that alleges that Precision is infringing on a Cellectis patent. The USPTO decision rejects Cellectis’ claims as being anticipated by or obvious in the context of […]
North Carolina biotechnology company Precision BioSciences is splitting into two divisions, one that will focus on humans and another that will focus on plant biotechnology. With the change, the Durham company is creating Precision PlantSciences, a subsidiary that will focus on developing the company’s technology for agricultural applications. Precision BioSciences will continue its genomics research […]
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.